Literatur
Christiansen C, JS Johansen, BL Riis (eds) (1987) Osteoporosis 1987, vol. 1 and 2, Nørhaven A/S, Viborg, Denmark
Consensus development conference: prophylaxis and treatment of osteoporosis (1987). Brit med J 295:914–916
Geusens P, Dequeker J, Verstraeten A, et al. (1986) Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions. Maturitas 8:281–289
Geusens P, Dequeker J (1986) Long-term effect of nandrolone decanoate, 1α-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a doubleblind controlled study. Bone and Mineral 1:347–357
Kopera H (1987) Letter to the editor. Brit med J 295:1277
Need AG, Morris HA, Hartley TF, et al. (1987) Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women. Calcif Tissue Int 41:7–10
Need AG, Chatterton BE, Walker CJ et al. (1986) Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. Maturitas 8:275–280
Nordin BEC, Need AG, Morris HA (1987) Letter to the editor. Brit med J 295:1276–1277
Riis BJ, Christiansen C, Johansen JS et al. (1988) Treatment of postmenopausal osteoporosis with nandrolone decanoate. Abstract in: Current Concepts in the Treatment of Established Osteoporosis with Deca-Durabolin. International Congress of Internal Medicine, Brussels
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kopera, H., Ziegler, R. Briefe an die Redaktion. Klin Wochenschr 67, 557–558 (1989). https://doi.org/10.1007/BF01719785
Issue Date:
DOI: https://doi.org/10.1007/BF01719785